000230.KS
Ildong Holdings Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 6,300.00
−3.82%Year over year
Reported trailing growth
- Revenue
- -3.8%
- EBITDA
- -53.7%
- EBIT
- +282.2%
- EPS
- -48.7%
- Free cash flow
- +2796.5%
- Operating cash flow
- +95.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -4.4%
- EBITDA
- -66.7%
- EBIT
- +603.6%
- Net income
- -82.7%
- EPS
- -82.7%
- Free cash flow
- +646.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026